Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects

Abstract Parkinson’s disease is a neurodegenerative disorder involving the basal ganglia that results in a host of motor and cognitive deficits. Dopamine-replacement therapy ameliorates some of the hallmark motor symptoms of Parkinson’s disease, but whether these medications improve deficits in resp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Peter Manza, Matthew Amandola, Vivekanand Tatineni, Chiang-shan R. Li, Hoi-Chung Leung
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/4b5c41d63cb540489f4fd82cd18e3152
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4b5c41d63cb540489f4fd82cd18e3152
record_format	dspace
spelling	oai:doaj.org-article:4b5c41d63cb540489f4fd82cd18e31522021-12-02T11:42:11ZResponse inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects10.1038/s41531-017-0024-22373-8057https://doaj.org/article/4b5c41d63cb540489f4fd82cd18e31522017-07-01T00:00:00Zhttps://doi.org/10.1038/s41531-017-0024-2https://doaj.org/toc/2373-8057Abstract Parkinson’s disease is a neurodegenerative disorder involving the basal ganglia that results in a host of motor and cognitive deficits. Dopamine-replacement therapy ameliorates some of the hallmark motor symptoms of Parkinson’s disease, but whether these medications improve deficits in response inhibition, a critical executive function for behavioral control, has been questioned. Several studies of Parkinson’s disease patients “on” and “off” (12-h withdrawal) dopaminergic medications suggested that dopamine-replacement therapy did not provide significant response inhibition benefits. However, these studies tended to include patients with moderate-to-advanced Parkinson’s disease, when the efficacy of dopaminergic drugs is reduced compared to early-stage Parkinson’s disease. In contrast, a few recent studies in early-stage Parkinson’s disease report that dopaminergic drugs do improve response inhibition deficits. Based on these findings, we hypothesized that Parkinson’s disease duration interacts with medication status to produce changes in cognitive function. To investigate this issue, we conducted a meta-analysis of studies comparing patients with Parkinson’s disease and healthy controls on tests of response inhibition (50 comparisons from 42 studies). The findings supported the hypothesis; medication benefited response inhibition in patients with shorter disease duration, whereas “off” medication, moderate deficits were present that were relatively unaffected by disease duration. These findings support the role of dopamine in response inhibition and suggest the need to consider disease duration in research of the efficacy of dopamine-replacement therapy on cognitive function in Parkinson’s disease.Peter ManzaMatthew AmandolaVivekanand TatineniChiang-shan R. LiHoi-Chung LeungNature PortfolioarticleNeurology. Diseases of the nervous systemRC346-429ENnpj Parkinson's Disease, Vol 3, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurology. Diseases of the nervous system RC346-429 Peter Manza Matthew Amandola Vivekanand Tatineni Chiang-shan R. Li Hoi-Chung Leung Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects
description	Abstract Parkinson’s disease is a neurodegenerative disorder involving the basal ganglia that results in a host of motor and cognitive deficits. Dopamine-replacement therapy ameliorates some of the hallmark motor symptoms of Parkinson’s disease, but whether these medications improve deficits in response inhibition, a critical executive function for behavioral control, has been questioned. Several studies of Parkinson’s disease patients “on” and “off” (12-h withdrawal) dopaminergic medications suggested that dopamine-replacement therapy did not provide significant response inhibition benefits. However, these studies tended to include patients with moderate-to-advanced Parkinson’s disease, when the efficacy of dopaminergic drugs is reduced compared to early-stage Parkinson’s disease. In contrast, a few recent studies in early-stage Parkinson’s disease report that dopaminergic drugs do improve response inhibition deficits. Based on these findings, we hypothesized that Parkinson’s disease duration interacts with medication status to produce changes in cognitive function. To investigate this issue, we conducted a meta-analysis of studies comparing patients with Parkinson’s disease and healthy controls on tests of response inhibition (50 comparisons from 42 studies). The findings supported the hypothesis; medication benefited response inhibition in patients with shorter disease duration, whereas “off” medication, moderate deficits were present that were relatively unaffected by disease duration. These findings support the role of dopamine in response inhibition and suggest the need to consider disease duration in research of the efficacy of dopamine-replacement therapy on cognitive function in Parkinson’s disease.
format	article
author	Peter Manza Matthew Amandola Vivekanand Tatineni Chiang-shan R. Li Hoi-Chung Leung
author_facet	Peter Manza Matthew Amandola Vivekanand Tatineni Chiang-shan R. Li Hoi-Chung Leung
author_sort	Peter Manza
title	Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects
title_short	Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects
title_full	Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects
title_fullStr	Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects
title_full_unstemmed	Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects
title_sort	response inhibition in parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/4b5c41d63cb540489f4fd82cd18e3152
work_keys_str_mv	AT petermanza responseinhibitioninparkinsonsdiseaseametaanalysisofdopaminergicmedicationanddiseasedurationeffects AT matthewamandola responseinhibitioninparkinsonsdiseaseametaanalysisofdopaminergicmedicationanddiseasedurationeffects AT vivekanandtatineni responseinhibitioninparkinsonsdiseaseametaanalysisofdopaminergicmedicationanddiseasedurationeffects AT chiangshanrli responseinhibitioninparkinsonsdiseaseametaanalysisofdopaminergicmedicationanddiseasedurationeffects AT hoichungleung responseinhibitioninparkinsonsdiseaseametaanalysisofdopaminergicmedicationanddiseasedurationeffects
_version_	1718395339044552704

Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects

Ejemplares similares